Key Highlights

  • EVE Health Group shares were up 12.00% at $0.014 during the 10 November 2026 trading session.
  • A binding Master Compounding and Profit Share Agreement was signed with Optimal Pharmacy Plus Stafford.
  • EVE is entitled to 75% of profit available for distribution, with no upfront or fixed fees payable by EVE.

EVE Health Group Limited (ASX:EVE) shares were trading higher during the 10 November 2026 session, up 12.00% at $0.014 at midday AEDT. The S&P/ASX 200 was also higher in the same session, up 1.13% at 9,131.90 around 12:30 pm AEDT. EVE is an Australian life sciences company developing pharmaceutical products and digital health platforms. The share price move came on the same day the company announced that it had signed a binding Master Compounding and Profit Share Agreement with Optimal Pharmacy Plus Stafford to commercialise its proprietary men's sexual health range in Australia.

About the company

EVE Health Group describes itself as building a vertically integrated health platform combining proprietary pharmaceutical products with digital education and prescribing pathways. Its lead Assets include Dyspro, a cannabinoid-based pastille, and Libbo, an oral soluble film for erectile dysfunction, which continues on its own registration pathway.

Compounding agreement announced on 10 November 2026

EVE will Supply its proprietary, patent-pending nano-emulsion technology, while Optimal is responsible for sourcing ingredients, compounding, dispensing and delivery. Profit available for distribution is shared 75% to EVE and 25% to Optimal, calculated after direct costs of ingredients, packaging, delivery and a fixed per-unit labour rate. EVE pays support fees to telehealth partners from its share.

The initial term is two years from first supply and renews automatically for successive 12-month periods unless notice is given. First supply is subject to conditions, including technology transfer and validation. The agreement contains no minimum volumes or guaranteed revenue, and EVE said it cannot yet estimate the Revenue it may generate.

Market context cited in the announcement

The announcement cited an Australian study of more than 100,000 men aged 45 and over in which around 61% reported some degree of erectile dysfunction. It also referred to an estimated US$5.7 billion global erectile dysfunction treatment market in 2026. EVE noted that compounded medicines are not entered on the Australian Register of Therapeutic Goods and are not assessed by the TGA.

Sector Context

Men's sexual health is increasingly accessed through telehealth, and pharmacy-led supply models are an emerging channel. Compounded products sit outside the registered medicines pathway, which the company says allows a different commercial route.

Risks to Consider

  • The agreement has no minimum volumes, and first supply depends on completing technology transfer and validation.
  • Revenue depends on prescribing by independent clinicians, patient demand, pricing and costs, and none can be estimated at this stage.
  • Compounded medicines are not assessed by the TGA for safety, quality or efficacy, and regulatory direction may change.

What to Watch Ahead

  • Completion of technology transfer and validation before first supply.
  • Engagement of telehealth partners and first patient supply.
  • Progress toward further compounded products and the Libbo registration pathway.

Final Word

EVE's compounding agreement gives it a capital-light route to market for its men's health range, with no minimum revenue guaranteed. First supply and the scale of patient Demand will be the key points to watch.